<div class="headers"><div>Table 1. Characteristics of the Patients at Baseline, According</div><div>to the Estimated Glomerular Filtration R</div><div>ate (eGFR).** P lus–minus values are means ±SD. The GFR at baseline was estimated according to the four-variable Modification of Diet in Renal Disease formula. Data on eGFR at baseline were not available for two patients in the empagliflozin group. There were no significant differences be-tween the study groups except with respect to high-density lipoprotein cholesterol (P = 0.02) and peripheral artery disease (P = 0.04) in pa-tients with an eGFR of 59 ml per minute per 1.73 m2 or less. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. 
To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. † T he body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ T he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. § T his ratio was measured in milligrams of albumin per grams of creatinine. ¶ L ow-density lipoprotein cholesterol was measured in 598 patients in the placebo group and 1201 in the empagliflozin group in patients with an eGFR of 59 ml per minute per 1.73 m2 or less and in 1711 patients in the placebo group and 3421 in the empagliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. ∥ H igh-density lipoprotein cholesterol and triglycerides were measured in 598 patients in the placebo group and 1202 in the empagliflozin group in patients with an eGFR of 59 ml per minute per 1.73 m2 or less and in 1711 patients in the placebo group and 3423 in the empa-gliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. ** I nformation on stroke history was not available for one patient in the placebo group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. †† I nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. ‡‡ C ardiac failure was determined according to the narrow standardized Medical Dictionary for Regulatory Activities query for the condition.Characteristic</div><div>Patients with eGFR of 59 ml per Minute per 1.73 m2 or Less</div><div>Patients with Minute per</div><div>eGFR of 60 ml per 1.73 m2 or MoreAge — yr</div><div>Placebo (N = 607) 67.1±8.2</div><div>Empagliflozin (N = 1212) 67.1±7.6</div><div>Placebo (N = 1726) 61.9±8.6</div><div>Empagliflozin (N = 3473) 61.7±8.5Male sex — no. (%)</div><div>418 (68.9)</div><div>816 (67.3)</div><div>1262 (73.1)</div><div>2518 (72.5)Body-mass index-!'</div><div>30.9±5.4</div><div>31.0±5.5</div><div>30.6±5.2</div><div>30.5±5.2Glycated hemoglobin — %-</div><div>8.03±0.85</div><div>8.07±0.86</div><div>8.10±0.84</div><div>8.07±0.84Interval of >10 yr since diagnosis of type 2 diabetes — no. (%)</div><div>422 (69.5)</div><div>794 (65.5)</div><div>917 (53.1)</div><div>1876 (54.0)Blood pressure — mm HgSystolic</div><div>136.4±18.7</div><div>136.1±18.0</div><div>135.6±16.7</div><div>135.0±16.6Diastolic</div><div>74.6±10.3</div><div>74.5±9.9</div><div>77.6±10.0</div><div>77.4±9.5Estimated glomerular filtration rate — ml/min/1.73 m2</div><div>48.6±7.8</div><div>48.4±8.2</div><div>82.7±16.6</div><div>83.1±17.1Urinary albumin-to-creatinine ratio — no. (%)§<30</div><div>283 (46.6)</div><div>566 (46.7)</div><div>1099 (63.7)</div><div>2223 (64.0)30 to 300</div><div>205 (33.8)</div><div>411 (33.9)</div><div>470 (27.2)</div><div>926 (26.7)>300</div><div>115 (18.9)</div><div>223 (18.4)</div><div>145 (8.4)</div><div>286 (8.2)Cholesterol — mg/dlLow-density lipoprotein^</div><div>85.0±36.1</div><div>84.4±35.8</div><div>84.8±35.1</div><div>86.5±36.0High-density lipoprotein]</div><div>42.9±10.7</div><div>44.2±12.5</div><div>44.4±11.5</div><div>44.7±11.7Triglycerides — mg/dl||</div><div>180.4±107.4</div><div>173.5±108.1</div><div>167.2±125.6</div><div>169.4±136.4Coronary artery disease</div><div>482 (79.4)</div><div>938 (77.4)</div><div>1281 (74.2)</div><div>2606 (75.0)History of stroke**</div><div>156 (25.7)</div><div>293 (24.2)</div><div>397 (23.0)</div><div>791 (22.8)Peripheral artery disease--</div><div>130 (21.4)</div><div>314 (25.9)</div><div>349 (20.2)</div><div>667 (19.2)Cardiac failure—</div><div>89 (14.7)</div><div>174 (14.4)</div><div>155 (9.0)</div><div>288 (8.3)Concomitant medication — no. (%)Angiotensin-converting-enzyme inhibitor or angiotensin-</div><div>502 (82.7)</div><div>1031 (85.1)</div><div>1366 (79.1)</div><div>2766 (79.6)receptor blockerBeta-blocker</div><div>415 (68.4)</div><div>829 (68.4)</div><div>1083 (62.7)</div><div>2226 (64.1)Diuretic</div><div>355 (58.5)</div><div>710 (58.6)</div><div>633 (36.7)</div><div>1336 (38.5)Calcium-channel blocker</div><div>227 (37.4)</div><div>446 (36.8)</div><div>561 (32.5)</div><div>1082 (31.2)Statin</div><div>461 (75.9)</div><div>966 (79.7)</div><div>1312 (76.0)</div><div>2663 (76.7)Aspirin</div><div>495 (81.5)</div><div>981 (80.9)</div><div>1432 (83.0)</div><div>2894 (83.3)Metformin</div><div>369 (60.8)</div><div>711 (58.7)</div><div>1365 (79.1)</div><div>2746 (79.1)Sulfonylurea</div><div>234 (38.6)</div><div>480 (39.6)</div><div>758 (43.9)</div><div>1534 (44.2)Insulin</div><div>357 (58.8)</div><div>699 (57.7)</div><div>778 (45.1)</div><div>1551 (44.7)</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="font-weight: bold; " class="bold ">Table 1. Characteristics of the Patients at Baseline, According</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="font-weight: bold; " class="bold ">to the Estimated Glomerular Filtration R</p></td>
<td style='border-top: 2px solid grey; text-align: left;'></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="font-weight: bold; " class="bold ">ate (eGFR).*</p></td>
<td style='border-top: 2px solid grey; text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="font-weight: bold; padding-left:20px; " class="indent1 bold ">* P lus–minus values are means ±SD. The GFR at baseline was estimated according to the four-variable Modification of Diet in Renal Disease formula. Data on eGFR at baseline were not available for two patients in the empagliflozin group. There were no significant differences be-tween the study groups except with respect to high-density lipoprotein cholesterol (P = 0.02) and peripheral artery disease (P = 0.04) in pa-tients with an eGFR of 59 ml per minute per 1.73 m2 or less. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. 
To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. † T he body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ T he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. § T his ratio was measured in milligrams of albumin per grams of creatinine. ¶ L ow-density lipoprotein cholesterol was measured in 598 patients in the placebo group and 1201 in the empagliflozin group in patients with an eGFR of 59 ml per minute per 1.73 m2 or less and in 1711 patients in the placebo group and 3421 in the empagliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. ∥ H igh-density lipoprotein cholesterol and triglycerides were measured in 598 patients in the placebo group and 1202 in the empagliflozin group in patients with an eGFR of 59 ml per minute per 1.73 m2 or less and in 1711 patients in the placebo group and 3423 in the empa-gliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. ** I nformation on stroke history was not available for one patient in the placebo group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. †† I nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an eGFR of 60 ml per minute per 1.73 m2 or more. ‡‡ C ardiac failure was determined according to the narrow standardized Medical Dictionary for Regulatory Activities query for the condition.</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="font-weight: bold; " class="bold ">Characteristic</p></td>
<td style='text-align: left;'><p style="font-weight: bold; padding-left:20px; " class="indent1 bold ">Patients with eGFR of 59 ml per Minute per 1.73 m2 or Less</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'><p style="font-weight: bold; " class="bold ">Patients with Minute per</p></td>
<td style='text-align: left;'><p style="font-weight: bold; " class="bold ">eGFR of 60 ml per 1.73 m2 or More</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Age — yr</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Placebo (N = 607) 67.1±8.2</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Empagliflozin (N = 1212) 67.1±7.6</p></td>
<td style='text-align: left;'><p style="" class="">Placebo (N = 1726) 61.9±8.6</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Empagliflozin (N = 3473) 61.7±8.5</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Male sex — no. (%)</p></td>
<td style='text-align: left;'><p style="" class="">418 (68.9)</p></td>
<td style='text-align: left;'><p style="" class="">816 (67.3)</p></td>
<td style='text-align: left;'><p style="" class="">1262 (73.1)</p></td>
<td style='text-align: left;'><p style="" class="">2518 (72.5)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Body-mass index-!'</p></td>
<td style='text-align: left;'><p style="" class="">30.9±5.4</p></td>
<td style='text-align: left;'><p style="" class="">31.0±5.5</p></td>
<td style='text-align: left;'><p style="" class="">30.6±5.2</p></td>
<td style='text-align: left;'><p style="" class="">30.5±5.2</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Glycated hemoglobin — %-</p></td>
<td style='text-align: left;'><p style="" class="">8.03±0.85</p></td>
<td style='text-align: left;'><p style="" class="">8.07±0.86</p></td>
<td style='text-align: left;'><p style="" class="">8.10±0.84</p></td>
<td style='text-align: left;'><p style="" class="">8.07±0.84</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Interval of >10 yr since diagnosis of type 2 diabetes — no. (%)</p></td>
<td style='text-align: left;'><p style="" class="">422 (69.5)</p></td>
<td style='text-align: left;'><p style="" class="">794 (65.5)</p></td>
<td style='text-align: left;'><p style="" class="">917 (53.1)</p></td>
<td style='text-align: left;'><p style="" class="">1876 (54.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Blood pressure — mm Hg</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Systolic</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">136.4±18.7</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">136.1±18.0</p></td>
<td style='text-align: left;'><p style="" class="">135.6±16.7</p></td>
<td style='text-align: left;'><p style="" class="">135.0±16.6</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Diastolic</p></td>
<td style='text-align: left;'><p style="" class="">74.6±10.3</p></td>
<td style='text-align: left;'><p style="" class="">74.5±9.9</p></td>
<td style='text-align: left;'><p style="" class="">77.6±10.0</p></td>
<td style='text-align: left;'><p style="" class="">77.4±9.5</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Estimated glomerular filtration rate — ml/min/1.73 m2</p></td>
<td style='text-align: left;'><p style="" class="">48.6±7.8</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">48.4±8.2</p></td>
<td style='text-align: left;'><p style="" class="">82.7±16.6</p></td>
<td style='text-align: left;'><p style="" class="">83.1±17.1</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Urinary albumin-to-creatinine ratio — no. (%)§</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class=""><30</p></td>
<td style='text-align: left;'><p style="" class="">283 (46.6)</p></td>
<td style='text-align: left;'><p style="" class="">566 (46.7)</p></td>
<td style='text-align: left;'><p style="" class="">1099 (63.7)</p></td>
<td style='text-align: left;'><p style="" class="">2223 (64.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">30 to 300</p></td>
<td style='text-align: left;'><p style="" class="">205 (33.8)</p></td>
<td style='text-align: left;'><p style="" class="">411 (33.9)</p></td>
<td style='text-align: left;'><p style="" class="">470 (27.2)</p></td>
<td style='text-align: left;'><p style="" class="">926 (26.7)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">>300</p></td>
<td style='text-align: left;'><p style="" class="">115 (18.9)</p></td>
<td style='text-align: left;'><p style="" class="">223 (18.4)</p></td>
<td style='text-align: left;'><p style="" class="">145 (8.4)</p></td>
<td style='text-align: left;'><p style="" class="">286 (8.2)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Cholesterol — mg/dl</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Low-density lipoprotein^</p></td>
<td style='text-align: left;'><p style="" class="">85.0±36.1</p></td>
<td style='text-align: left;'><p style="" class="">84.4±35.8</p></td>
<td style='text-align: left;'><p style="" class="">84.8±35.1</p></td>
<td style='text-align: left;'><p style="" class="">86.5±36.0</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">High-density lipoprotein]</p></td>
<td style='text-align: left;'><p style="" class="">42.9±10.7</p></td>
<td style='text-align: left;'><p style="" class="">44.2±12.5</p></td>
<td style='text-align: left;'><p style="" class="">44.4±11.5</p></td>
<td style='text-align: left;'><p style="" class="">44.7±11.7</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Triglycerides — mg/dl||</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">180.4±107.4</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">173.5±108.1</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">167.2±125.6</p></td>
<td style='text-align: left;'><p style="" class="">169.4±136.4</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Coronary artery disease</p></td>
<td style='text-align: left;'><p style="" class="">482 (79.4)</p></td>
<td style='text-align: left;'><p style="" class="">938 (77.4)</p></td>
<td style='text-align: left;'><p style="" class="">1281 (74.2)</p></td>
<td style='text-align: left;'><p style="" class="">2606 (75.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">History of stroke**</p></td>
<td style='text-align: left;'><p style="" class="">156 (25.7)</p></td>
<td style='text-align: left;'><p style="" class="">293 (24.2)</p></td>
<td style='text-align: left;'><p style="" class="">397 (23.0)</p></td>
<td style='text-align: left;'><p style="" class="">791 (22.8)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Peripheral artery disease--</p></td>
<td style='text-align: left;'><p style="" class="">130 (21.4)</p></td>
<td style='text-align: left;'><p style="" class="">314 (25.9)</p></td>
<td style='text-align: left;'><p style="" class="">349 (20.2)</p></td>
<td style='text-align: left;'><p style="" class="">667 (19.2)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Cardiac failure—</p></td>
<td style='text-align: left;'><p style="" class="">89 (14.7)</p></td>
<td style='text-align: left;'><p style="" class="">174 (14.4)</p></td>
<td style='text-align: left;'><p style="" class="">155 (9.0)</p></td>
<td style='text-align: left;'><p style="" class="">288 (8.3)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Concomitant medication — no. (%)</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Angiotensin-converting-enzyme inhibitor or angiotensin-</p></td>
<td style='text-align: left;'><p style="" class="">502 (82.7)</p></td>
<td style='text-align: left;'><p style="" class="">1031 (85.1)</p></td>
<td style='text-align: left;'><p style="" class="">1366 (79.1)</p></td>
<td style='text-align: left;'><p style="" class="">2766 (79.6)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">receptor blocker</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Beta-blocker</p></td>
<td style='text-align: left;'><p style="" class="">415 (68.4)</p></td>
<td style='text-align: left;'><p style="" class="">829 (68.4)</p></td>
<td style='text-align: left;'><p style="" class="">1083 (62.7)</p></td>
<td style='text-align: left;'><p style="" class="">2226 (64.1)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Diuretic</p></td>
<td style='text-align: left;'><p style="" class="">355 (58.5)</p></td>
<td style='text-align: left;'><p style="" class="">710 (58.6)</p></td>
<td style='text-align: left;'><p style="" class="">633 (36.7)</p></td>
<td style='text-align: left;'><p style="" class="">1336 (38.5)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Calcium-channel blocker</p></td>
<td style='text-align: left;'><p style="" class="">227 (37.4)</p></td>
<td style='text-align: left;'><p style="" class="">446 (36.8)</p></td>
<td style='text-align: left;'><p style="" class="">561 (32.5)</p></td>
<td style='text-align: left;'><p style="" class="">1082 (31.2)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Statin</p></td>
<td style='text-align: left;'><p style="" class="">461 (75.9)</p></td>
<td style='text-align: left;'><p style="" class="">966 (79.7)</p></td>
<td style='text-align: left;'><p style="" class="">1312 (76.0)</p></td>
<td style='text-align: left;'><p style="" class="">2663 (76.7)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Aspirin</p></td>
<td style='text-align: left;'><p style="" class="">495 (81.5)</p></td>
<td style='text-align: left;'><p style="" class="">981 (80.9)</p></td>
<td style='text-align: left;'><p style="" class="">1432 (83.0)</p></td>
<td style='text-align: left;'><p style="" class="">2894 (83.3)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Metformin</p></td>
<td style='text-align: left;'><p style="" class="">369 (60.8)</p></td>
<td style='text-align: left;'><p style="" class="">711 (58.7)</p></td>
<td style='text-align: left;'><p style="" class="">1365 (79.1)</p></td>
<td style='text-align: left;'><p style="" class="">2746 (79.1)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Sulfonylurea</p></td>
<td style='text-align: left;'><p style="" class="">234 (38.6)</p></td>
<td style='text-align: left;'><p style="" class="">480 (39.6)</p></td>
<td style='text-align: left;'><p style="" class="">758 (43.9)</p></td>
<td style='text-align: left;'><p style="" class="">1534 (44.2)</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Insulin</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">357 (58.8)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">699 (57.7)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">778 (45.1)</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">1551 (44.7)</p></td>
</tr>
</tbody>
</table>
